A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Diabetes & Metabolism Journal
;
: 261-273, 2014.
Article
Dans Anglais
| WPRIM
| ID: wpr-103499
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies for glycemic control is now available, management of T2DM remains complex and challenging. The kidneys contribute immensely to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. In this review, we provide an overview of two globally-approved SGLT2 inhibitors, dapagliflozin and canagliflozin, and discuss their effects and safety. This information will help clinicians to decide whether these drugs will benefit their patients.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Santé publique
/
Prévalence
/
Diabète de type 2
/
Traitement médicamenteux
/
Absorption
/
Canagliflozine
/
Glucose
/
Homéostasie
/
Hypoglycémiants
/
Insuline
Type d'étude:
Étude de prévalence
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Diabetes & Metabolism Journal
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS